Skip to content

0.01% Hypochlorous Acid in the Treatment of Blepharitis

Effect of Hypochlorous Acid on Blepharitis Through Ultrasonic Atomization: a Randomized Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05608980
Enrollment
100
Registered
2022-11-08
Start date
2022-07-01
Completion date
2023-05-01
Last updated
2022-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blepharitis

Keywords

Blepharitis, Hypochlorous Acid, Eyelid cleanser, Eyelid hygiene, Meibomian gland dysfunction

Brief summary

This is a multi-center, multidisciplinary, open-label, randomized controlled prospective clinical study.

Interventions

once daily 0.01% hypochlorous acid topical treatment via ultrasonic atomization for 2 weeks

DRUGPlacebo

once daily eyelid wipes for 2 weeks

Sponsors

ShuGuang Hospital
CollaboratorOTHER
Eye & ENT Hospital of Fudan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Intervention model description

A prospective, controlled, randomized study.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age 18 or older. 2. Anterior or mixed (anterior + posterior) blepharitis. 3. Similar clinical condition of both eyes. 4. A negative urine pregnancy test result for women of childbearing potential 5. Normal lid position and closure 6. Ability to understand and provide informed consent to participate in this study 7. Willingness to follow study instructions and likely to complete all required visits.

Exclusion criteria

1. Any ocular surface disease other than blepharitis. 2. Known allergy to hypochlorous acid or boric acid. 3. Eye surgery in the last 6 months. 4. History of Stevens-Johnson syndrome or ocular pemphigoid 5. Ocular trauma in the last 6 months. 6. Use of contact lenses in the last 6 months. 7. Pregnancy or lactation. 8. Daily use of makeup on lashes. 9. Any ocular or systemic medication that might affect the ocular microbiota (antibiotics, immunosuppressants, steroids). 10. Pregnant or lactating women 11. Signs of current infection, including fever and current treatment with antibiotics 12. Liver, renal, or hematologic disease 13. The use of any other investigational drug

Design outcomes

Primary

MeasureTime frameDescription
OSDIChange from baseline OSDI at 2 weeks0-100 score based on the ocular surface disease index (OSDI) questionnaire
meibum qualityChange from baseline meibum quality score at 2 weeksMeibum quality were measured by using firm digital pressure applied over 5 lower lid glands. Meibum quality was graded as: grade 0, clear; grade 1, cloudy; grade 2, cloudy with granular debris; and grade 3, thick like toothpaste.
Corneal fluorescein stainingChange from baseline corneal fluorescein staining at 2 weeksscored by Oxford staining score
FBUTChange from baseline FTBUT at 2 weeksfluorescent tear break up time fluorescein tear film break-up time

Countries

China

Contacts

Primary ContactJiaxu Hong
jiaxu_hong@163.com13917440201

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026